Cns Pharmaceuticals, INC 8-K filings

CNS Pharmaceuticals filed an amendment to its previous 8-K report to include a legal opinion regarding the issuance of shares and warrants.

CNS Pharmaceuticals, Inc. has announced a registered direct offering and concurrent private placement expected to raise $1.37 million in gross proceeds.

CNS Pharmaceuticals has enacted a 1-for-50 reverse stock split to increase its per share trading price and comply with Nasdaq's minimum share price rule.

CNS Pharmaceuticals announced its first quarter 2024 financial results, highlighting a reduced net loss and the completion of enrollment in its pivotal Berubicin trial for Glioblastoma Multiforme (GBM), with topline data expected in the first half of 2025.

CNS Pharmaceuticals has been granted an extension until July 15, 2024, by the Nasdaq Hearings Panel to regain compliance with listing rules regarding minimum stockholders' equity and bid price.

CNS Pharmaceuticals' shareholders approved an increase in authorized shares and amendments to the 2020 Equity Plan at the annual meeting on April 30, 2024.

CNS Pharmaceuticals is advancing its lead drug candidate, Berubicin, through a potentially pivotal clinical trial for the treatment of glioblastoma multiforme (GBM), with topline data expected in the first half of 2025.

CNS Pharmaceuticals reported its 2023 financial results, highlighted by the completion of enrollment and a positive interim futility analysis for its Berubicin clinical trial.

CNS Pharmaceuticals has received a delisting notice from Nasdaq due to its stock price falling below $1.00 and a stockholders' equity deficiency, and is taking steps to regain compliance.

CNS Pharmaceuticals has received notice from Nasdaq that it does not meet the minimum stockholders' equity requirement and faces potential delisting unless it successfully appeals.

CNS Pharmaceuticals has completed a $3.7 million public offering, issuing common stock and warrants to fund its CNS-201 trial and for general working capital.

CNS Pharmaceuticals has appointed Amy Mahery as an independent director, effective upon the completion of the company's financing.